Add as a preferred source on GooglePTC Therapeutics Raises 2026 Product Revenue Outlook, Now $960 Million to $990 Million
The company also projects total revenue of $1.29 billion to $1.32 billion and expects cash flow breakeven in 2026.
PTC Therapeutics, Inc. (PTCT) raised its 2026 product revenue outlook to $960 million to $990 million and expects to complete the rolling biologics license application (BLA) submission for ST-920 in Q4 2026.
The company projects total revenue of $1.29 billion to $1.32 billion for 2026. Management also expects PTC to reach cash flow breakeven in 2026.
Sephience remains in the early stages of launch, with more than 2,000 active patients. Management said most eligible U.S. patients have yet to try the treatment and expressed confidence in peak sales potential above $2 billion.
PTC sees potential approval and launch for ST-920 in 2027. Management said the therapy could be accretive in 2027.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.